American Heart Journal
Volume 151, Issue 2 , Pages 273-281 , February 2006

Are statins created equal? Evidence from randomized trials of pravastatin, simvastatin, and atorvastatin for cardiovascular disease prevention

  • Zheng Zhou, MD, PhD

      Affiliations

    • Department of Epidemiology and Biostatistics, McGill University, Montréal, Quebec, Canada
    • Division of Clinical Epidemiology, Montréal General Hospital, Montréal, Quebec, Canada
    • ,
  • Elham Rahme, PhD

      Affiliations

    • Department of Epidemiology and Biostatistics, McGill University, Montréal, Quebec, Canada
    • Division of Clinical Epidemiology, Montréal General Hospital, Montréal, Quebec, Canada
    • ,
  • Louise Pilote, MD, MPH, PhD

      Affiliations

    • Department of Epidemiology and Biostatistics, McGill University, Montréal, Quebec, Canada
    • Division of Clinical Epidemiology, Montréal General Hospital, Montréal, Quebec, Canada
    • Corresponding Author InformationReprint requests: Louise Pilote MD, MPH, PhD, Division of Clinical Epidemiology, L10-421, Montreal General Hospital, 1650 Cedar Avenue, Montreal, Quebec, Canada H3G 1A4.

Received 1 November 2004 ,Accepted 1 April 2005.

References 

  1. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995;333:1301–1307
  2. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996;335:1001–1009
  3. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339:1349–1357
  4. Sacks FM, Tonkin AM, Shepherd J, et al. Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors: the Prospective Pravastatin Pooling Project. Circulation. 2000;102:1893–1900
  5. Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002;360:1623–1630
  6. The ALLHAT Officers and Coordinators for the ALLHAT Collborative Research. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA. 2002;288:2998–3007
  7. The Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383–1389
  8. Heart Protection Study Collaborative Group. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7–22
  9. Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003;361:1149–1158
  10. Topol EJ. Intensive statin therapy—a sea change in cardiovascular prevention. N Engl J Med. 2004;350:1562–1564
  11. Mamdani MM, Tu JV. Did the major clinical trials of statins affect prescribing behaviour?. CMAJ. 2001;164:1695–1696
  12. Jackevicius CA, Anderson GM, Leiter L, et al. Use of the statins in patients after acute myocardial infarction: does evidence change practice?. Arch Intern Med. 2001;161:183–188
  13. Jackevicius CA, Tu K, Filate WA, et al. Trends in cardiovascular drug utilization and drug expenditures in Canada between 1996 and 2001. Can J Cardiol. 2003;19:1359–1366
  14. McKenney JM, Jones PH, Adamczyk MA, et al. Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial. Curr Med Res Opin. 2003;19:689–698
  15. McAlister FA, Laupacis A, Wells GA, et al. Users' guides to the medical literature: XIX. Applying clinical trial results: B. Guidelines for determining whether a drug is exerting (more than) a class effect. JAMA. 1999;282:1371–1377
  16. Nissen SE, Tuzcu EM, Schoenhagen P, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA. 2004;291:1071–1080
  17. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495–1504
  18. Bucher HC, Guyatt GH, Griffith LE, et al. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol. 1997;50:683–691
  19. Higgins JP, Whitehead A. Borrowing strength from external trials in a meta-analysis. Stat Med. 1996;15:2733–2749
  20. Song F, Altman DG, Glenny AM, et al. Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses. BMJ. 2003;326:472
  21. Fisher LD, Gent M, Buller HR. Active-control trials: how would a new agent compare with placebo? A method illustrated with clopidogrel, aspirin, and placebo. Am Heart J. 2001;141:26–32
  22. Song F, Glenny AM, Altman DG. Indirect comparison in evaluating relative efficacy illustrated by antimicrobial prophylaxis in colorectal surgery. Control Clin Trials. 2000;21:488–497
  23. Bjerre LM, LeLorier J. Do statins cause cancer? a meta-analysis of large randomized clinical trial. Am J Med. 2001;110:716–723
  24. Miettinen TA, Pyorala K, Olsson AG, et al. Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris: findings from the Scandinavian Simvastatin Survival Study (4S). Circulation. 1997;96:4211–4218
  25. Haffner SM, Alexander CM, Cook TJ, et al. Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: subgroup analyses in the Scandinavian Simvastatin Survival Study. Arch Intern Med. 1999;159:2661–2667
  26. Collins R, Armitage J, Parish S, et al. MRC/BHF heart protection study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet. 2003;361:2005–2016
  27. Collins R, Armitage J, Parish S, et al. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet. 2004;363:757–767
  28. Lewis SJ, Moye LA, Sacks FM, et al. Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Results of the Cholesterol and Recurrent Events (CARE) trial. Ann Intern Med. 1998;129:681–689
  29. Lewis SJ, Sacks FM, Mitchell JS, et al. Effect of pravastatin on cardiovascular events in women after myocardial infarction: the cholesterol and recurrent events (CARE) trial. J Am Coll Cardiol. 1998;32:140–146
  30. Goldberg RB, Mellies MJ, Sacks FM, et al. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The care investigators. Circulation. 1998;98:2513–2519
  31. Plehn JF, Davis BR, Sacks FM, et al. Reduction of stroke incidence after myocardial infarction with pravastatin: the Cholesterol and Recurrent Events (CARE) study. The CARE investigators. Circulation. 1999;99:216–223
  32. Hunt D, Young P, Simes J, et al. Benefits of pravastatin on cardiovascular events and mortality in older patients with coronary heart disease are equal to or exceed those seen in younger patients: results from the LIPID trial. Ann Intern Med. 2001;134:931–940
  33. Hague W, Forder P, Simes J, et al. Effect of pravastatin on cardiovascular events and mortality in 1516 women with coronary heart disease: results from the Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) study. Am Heart J. 2003;145:643–651
  34. Keech A, Colquhoun D, Best J, et al. Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trial. Diabetes Care. 2003;26:2713–2721
  35. Tonkin AM, Colquhoun D, Emberson J, et al. Effects of pravastatin in 3260 patients with unstable angina: results from the LIPID study. Lancet. 2000;356:1871–1875
  36. Marschner IC, Colquhoun D, Simes RJ, et al. Long-term risk stratification for survivors of acute coronary syndromes. Results from the Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Study. LIPID study investigators. J Am Coll Cardiol. 2001;38:56–63
  37. The LIPID Study Group. Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow-up. Lancet. 2002;359:1379–1387
  38. Simes J, Furberg CD, Braunwald E, et al. Effects of pravastatin on mortality in patients with and without coronary heart disease across a broad range of cholesterol levels. The Prospective Pravastatin Pooling project. Eur Heart J. 2002;23:207–215
  39. L'Abbe KA, Detsky AS, O'Rourke K. Meta-analysis in clinical research. Ann Intern Med. 1987;107:224–233
  40. Ferrer RL. Graphical methods for detecting bias in meta-analysis. Fam Med. 1998;30:579–583
  41. Whitehead A. Combining estimates of a treatment difference across trials. Meta-analysis of controlled clinical trials. In:  Senn S,  Barnett V editor. Statistics in Practice. Chichester: John Wiley & Sons Ltd; 2002;p. 57–98
  42. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–188
  43. Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA. 2001;285:1711–1718
  44. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004;364:685–696
  45. Athyros VG, Papageorgiou AA, Mercouris BR, et al. Treatment with atorvastatin to the National Cholesterol Educational Program goal versus “usual” care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Curr Med Res Opin. 2002;18:220–228
  46. LaRosa JC. New and emerging data from clinical trials of statins. Curr Med Rep. 2004;6:12–19
  47. LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease. JAMA. 1999;282:2340–2346
  48. Pignone M, Phillips C, Mulrow C. Use of lipid lowering drugs for primary prevention of coronary heart disease: meta-analysis of randomised trials. BMJ. 2000;321:983–986
  49. Hebert PR, Gaziano JM, Chan KS, et al. Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials. JAMA. 1997;278:313–321
  50. Whitehead A. Meta-analysis using individual patient data. Meta-analysis of controlled clinical trials. In:  Senn S,  Barnett V editor. Statistics in Practice. Chichester: John Wiley & Sons Ltd; 2002;p. 99–150
  51. Whitehead A. Dealing with heterogeneity. Meta-analysis of controlled clinical trials. In:  Senn S,  Barnett V editor. Statistics in Practice. Chichester: John Wiley & Sons Ltd; 2002;p. 151–174
  52. Jones P, Kafonek S, Laurora I, et al. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol. 1998;81:582–587
  53. Canadian Pharmacists Association. Compendium of pharmaceuticals and specialities. Canada: Canadian Pharmacist Association; 2002;

 Dr Zhou was supported by a research scholarship from the Natural Science and Engineering Research Council of Canada (NSERC) and a fellowship from the Canadian Cardiovascular Outcome Research Team (CCORT). Dr Rahme is a research scholar funded by the Arthritis Society. Dr Pilote is a research scholar of the Canadian Institute for Health Research (CIHR) and a William Dawson Professor at McGill University. None of the authors has financial interest or conflict with regard to the content discussed in this manuscript.

PII: S0002-8703(05)00361-3

doi: 10.1016/j.ahj.2005.04.003

American Heart Journal
Volume 151, Issue 2 , Pages 273-281 , February 2006

Article Tools

* Image Usage & Resolution